{"protocolSection": {"identificationModule": {"nctId": "NCT05337137", "orgStudyIdInfo": {"id": "CA224-106"}, "secondaryIdInfos": [{"id": "2021-003606-53", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1267-1579", "type": "OTHER", "domain": "WHO"}], "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer", "officialTitle": "A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma", "acronym": "RELATIVITY-106"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC)."}, "conditionsModule": {"conditions": ["Carcinoma, Hepatocellular"], "keywords": ["Hepatocellular Carcinoma", "HCC", "Liver Cancer", "Relatlimab", "Nivolumab", "Bevacizumab", "First line HCC"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 162, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A: Relatlimab + Nivolumab + Bevacizumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Relatlimab", "Drug: Nivolumab", "Drug: Bevacizumab"]}, {"label": "Arm B: Placebo + Nivolumab + Bevacizumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Bevacizumab", "Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Relatlimab", "description": "Specified dose on specified days", "armGroupLabels": ["Arm A: Relatlimab + Nivolumab + Bevacizumab"], "otherNames": ["BMS-986016"]}, {"type": "DRUG", "name": "Nivolumab", "description": "Specified dose on specified days", "armGroupLabels": ["Arm A: Relatlimab + Nivolumab + Bevacizumab", "Arm B: Placebo + Nivolumab + Bevacizumab"], "otherNames": ["BMS-936558", "Opdivo"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Specified dose on specified days", "armGroupLabels": ["Arm A: Relatlimab + Nivolumab + Bevacizumab", "Arm B: Placebo + Nivolumab + Bevacizumab"], "otherNames": ["Avastin"]}, {"type": "OTHER", "name": "Placebo", "description": "Specified dose on specified days", "armGroupLabels": ["Arm B: Placebo + Nivolumab + Bevacizumab"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)\n* Na\u00efve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs \u2265 6 months after treatment completion and the case is discussed with BMS medical team)\n* Child-Pugh score of 5 or 6 (ie, Child-Pugh A)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nExclusion Criteria:\n\n* Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC\n* Prior allogenic stem cell or solid organ transplantation\n* Untreated symptomatic central nervous system (CNS) metastases\n* Clinically significant ascites as defined by:\n\n  i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment\n\nOther protocol-defined inclusion/exclusion criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "BMS Study Connect Contact Center www.BMSStudyConnect.com", "role": "CONTACT", "phone": "855-907-3286", "email": "Clinical.Trials@bms.com"}, {"name": "First line of the email MUST contain NCT # and Site #.", "role": "CONTACT"}], "overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05337137.html"}]}}, "hasResults": false}